8th Annual Tumour Models, San Francisco, CA, Jan 30-Feb 01, 2024

Conference

genOway talk

Event
-
January 23, 2024

Jan 30-Feb 01, 2024

Implementing State-of-the-Art, Reproducible Preclinical Oncology Models to Accelerate Your Candidate’s Clinical Translatability

8th Tumour Models San Francisco

genOway’s presentation:

How to enhance translatability of immunotherapies in preclinical models

  • Outlining BRGSF-HIS mice: Immunodeficient mice displaying functional human lymphoid and myeloid compartments, without GvHD and side effects
  • Examining human cells functionality and assessing immune modulation induced by biologics in BRGSF-HIS model
  • Showcase of assessment of immune targeting agents in immune checkpoint humanized models

Register your place!

8th Annual Tumour Models, San Francisco, CA, Jan 30-Feb 01, 2024

Get in touch about

Let us know how we can help

In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Other news & events

8th Annual Tumour Models, San Francisco, CA, Jan 30-Feb 01, 2024
Conference
genOway talk
Event
-
Jan 2024
Read on
Another technological achievement for genOway's humanized ICP (immune checkpoint) models, used successfully by Curadev Pharma in the preclinical trials of its drug candidate CRD3874 for the treatment of advanced/metastatic solid cancers
2023
IND (Investigational New Drug)
News
-
Aug 2023
Read on
Sigma-Aldrich and genOway expand their CRISPR/Cas9 strategic alliance
2022
Intellectual property
News
-
Sep 2022
Read on
genOway grants the leading UK academic research funder a non-exclusive license for CRISPR/Cas9 technology
2022
Intellectual property
News
-
Jan 2022
Read on
ERS Genomics and genOway enter CRISPR/Cas9 agreement
2021
Intellectual property
News
-
Jun 2021
Read on